Dr Erfan Nur (Amsterdam University Medical Center, the Netherlands) discussed personalised treatment options and their importance for patients with SCD [1]. Each SCD patient has a unique set of factors to consider in the treatment decision process: genotype (e.g. haemoglobin [Hb]SS, HbSC, HbSÎČ0, HbSÎČ+), disease burden (relative contribution of pathophysiologies: vaso-occlusion, haemolytic anaemia), complications (e.g. acute coronary syndrome, stroke, splenic sequestration), treatment factors (e.g. efficacy, side effects, availability, clinical trial eligibility), care network (level of access), and impact on daily and social life.
Before 2017, treatment and management options for SCD were limited to blood transfusions, dietary supplements, haematopoietic stem cell transplant (HSCT), hydroxyurea (HU), alternative management (e.g. rest, hydration), analgesics, and dietary supplements. Potential limitations of these therapies are adverse events, limited availability, and in some cases limited efficacy [2].
For example, blood transfusion treatment showed a 92% reduction of stroke risk versus placebo in the STOP trial (NCT00006182). Active transfusions are performed in emergency situations whereas chronic transfusions are, for instance, performed to prevent cerebrovascular disease or frequent pain episodes [3]. However, transfusions have potential long-term complications, including iron overload, red blood cell allo-immunisation, and delayed haemolytic reactions.
So far, HSCT is the only potentially curative treatment, but it also has several limitations. Only 18% of patients have a matched sibling donor and are eligible for this treatment. There are two types of HSCT treatment: myeloablative and non-myeloablative conditioning. The latter is associated with reduced transplant-related complications, such as reduced toxicity, but leads to higher graft failure rates [4].
HU was one of the earliest promising drugs in SCD and is, to date, the mainstay of SCD therapy in adults [5]. HU increases Hb levels, resulting in a reduced annual rate of vaso-occlusive crises (VOCs), reduced frequency of pain crises, and a reduction in stroke risk. However, not all patients obtain a response and adherence to therapy remains an issue [6]. Since 2017, HU is also approved for children. Paediatric studies in SCD show similar safety of HU as in adults, providing an invaluable resource to prevent organ damage in children.
Over the past years, new treatment options have become available or are in clinical development, such as L-glutamine (an antioxidant), crizanlizumab (an anti-P-selectin monoclonal antibody), and voxelotor (a sickled haemoglobin polymerisation inhibitor) [2]. L-glutamine reduced the VOC frequency by 25% and hospitalisation by 33% versus placebo [7]. Crizanlizumab significantly reduced the annual rate of VOCs by 45% compared with placebo, demonstrated a longer time to first VOC, and little risk for immunogenicity and hypersensitivity reactions [8]. Voxelotor reduced levels of haemolysis markers and increased Hb levels and reduced the annualised incident rate of VOCs [9]. Gene therapies are also under investigation, including LentiGlobin, CTX001, OTQ923, and HIX763.
Dr Nur concluded, âconsideration of treatment options must be in the context of specific patient-related factors to come to a personalised treatment decisionâ.
- Nur E. Knowing the options: personalizing treatment of SCD. 1UiHSAT-SL3, EHA 2021 Virtual Congress, 9â17 June.
- Cisneros GS and Thein SL. Front Physiol 2020;11:435.
- Adams RJ, et al. N Engl J Med 1998;339:5â11.
- Nur E, et al. HemaSphere 2019;3(S1):1027â8.
- Yasara N, et al. Orphanet J Rare Dis 2021;16:114.
- Thornburg CD, et al. Blood 2012;120(22):4304â10.
- Niihara Y, et al. BMC Blood Disord 2005;5:4.
- Ataga KI, et al. N Engl J Med 2017;376:429â39.
- Howard J, et al. HemaSphere 2020;4(S1)EP1540:714.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Gene therapy: A promising approach for hereditary haemoglobinopathies Next Article
Luspatercept improved anaemia in patients with non-transfusion-dependent ÎČ-thalassaemia »
« Gene therapy: A promising approach for hereditary haemoglobinopathies Next Article
Luspatercept improved anaemia in patients with non-transfusion-dependent ÎČ-thalassaemia »
Table of Contents: EHA 2021
Featured articles
Lymphoma
Immuno-oncology agents are effective in treating classic Hodgkinâs lymphoma
MATRix with ASCT: best long-term survival for primary CNS lymphoma
Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma
The journey ahead for CAR T-cell therapy in r/r follicular lymphoma
ZUMA-5 vs SCHOLAR-5: Axicabtagene ciloleucel significantly improves FL outcome
Promising chemo-free treatment options in r/r DLBCL
Leukaemia
Sabatolimab achieved durable responses in patients with high-risk MDS and AML
Final analysis of EURO-SKI: primary endpoints met in chronic myeloid leukaemia
Favourable outcomes with zanubrutinib versus ibrutinib in patients with r/r CLL
Oral azacitidine improves overall survival in patients with acute myeloid leukaemia
Reduced-intensity conditioning ASCT is effective in older patients with AML
ELEVATE-TN: Acalabrutinib shows long-term efficacy in chronic lymphocytic leukaemia
ELEVATE-RR: Acalabrutinib demonstrates similar efficacy and better safety versus ibrutinib
Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL
GLOW: Ibrutinib + venetoclax showed superior PFS as first-line CLL treatment
Myeloma and Myelofibrosis
Novel targets in myelofibrosis: overview of emergent therapies
Immune therapy of multiple myeloma
MAIA results confirm superior efficacy of daratumumab with standard-of-care
ANDROMEDA: Addition of daratumumab showed superior efficacy in patients with AL amyloidosis
Thrombotic and Thrombocytopenic Disorders including COVID-19 related
Acquired TTP: new treatments and updated guidelines
Maternal screening to prevent foetal and neonatal alloimmune thrombocytopenia
Fostamatinib effectively increased platelet counts in immune thrombocytopenic purpura
Physiopathology of coagulopathy in haematological malignancies and COVID-19
Haemostatic abnormalities are associated with mortality in COVID-19
Mechanisms of COVID-19 vaccine-induced thrombotic thrombocytopenia
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: discovery and diagnosis
Haemoglobinopathies
Luspatercept improved anaemia in patients with non-transfusion-dependent ÎČ-thalassaemia
Personalising treatment for sickle cell disease
Gene therapy: A promising approach for hereditary haemoglobinopathies
Related Articles
August 5, 2021
Letter from the Editor
August 5, 2021
Personalising treatment for sickle cell disease
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy